on AMOEBA (EPA:ALMIB)
Amoéba's AXPERA Shows Promising Results in Brazilian Crop Trials
Amoéba, in collaboration with Koppert, has conducted successful field trials in Brazil to evaluate the effectiveness of its AXPERA biofungicide technology on key crops like soya and oranges. Brazil's dynamic bio-input market, forecasted to reach €1 billion by 2025, presents a significant opportunity for AXPERA. The trials have shown encouraging results in managing Asian rust in soya and bacterial canker in orange trees, potentially reducing copper use.
The Brazilian regulatory framework, which supports accelerated registration and use of bio-inputs, could favor the integration of AXPERA. Amoéba aims to commercialize AXPERA in Brazil by 2028, pending approval from relevant ministries. This aligns with its strategy to extend its market reach beyond Europe and the U.S.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news